June 15, 2026 FDA Approves KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each With WELIREG® (belzutifan), for Adjuvant Treatment of Certain Patients With Clear Cell Renal Cell Carcinoma (ccRCC)
June 15, 2026 Joseph Carrizales CRE Publishes Free Updated Cap Rate Data and Industrial Asset Evaluation Resource for Detroit–Toledo Corridor Property Owners
June 15, 2026 BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Nuvalent, Inc. (Nasdaq – NUVL), Dana Incorporated (NYSE – DAN), SUNation Energy, Inc. (Nasdaq – SUNE), Taylor Morrison Home Corporation (NYSE – TMHC)
June 15, 2026 SRAD Investors Have Opportunity to Lead Sportradar Group AG Securities Fraud Lawsuit with the Schall Law Firm
